Radiobiology Research Institute, Churchill Hospital, Headington, Oxford
MD, PhD, FRCP
Emeritus Associate Professor
- Honorary Consultant in Medical Oncology
I qualified as a doctor at Charing Cross Hospital Medical School and trained in Medical Oncology at the Royal Marsden Hospital London and Churchill Hospital Oxford. Following a PhD with Alan Ashworth at Chester Beatty Laboratories in London, my postdoctoral training was supported by MRC Clinician Scientist and Cancer Research UK Senior Clinical Fellowships and HEFCE Clinical Senior Lectureship. I was Associate Professor and Honorary Consultant in Medical Oncology, Department of Oncology, University of Oxford from 2001 to 2021, now Emeritus Associate Professor, Nuffield Department of Surgical Sciences, University of Oxford. My laboratory research group uses basic, translational and clinical research to investigate the role of IGFs in prostate cancer and is supported by collaborating clinicians and scientists in Oxford and elsewhere.
GeneFEAST: the pivotal, gene-centric step in functional enrichment analysis interpretation
TAYLOR A., (2023)
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM. et al, (2023), Br J Cancer
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.
Coupe N. et al, (2023), Cell Oncol (Dordr), 46, 391 - 407
CHK1 inhibition exacerbates replication stress induced by IGF blockade
Macaulay V. et al, (2021), Oncogene
IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits.
Mills JV. et al, (2021), Discov Oncol, 12